1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr H Barron
|
|||
b)
|
Position/status
|
Chief
Scientific Officer and President, R&D
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2018 under the Company's 2017 Performance Share
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$35.6978
|
86,855
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Connor
|
|||
b)
|
Position/status
|
President,
Global Vaccines
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
63,501
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Conrad
|
|||
b)
|
Position/status
|
SVP,
Human Resources
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Following the vesting of Ordinary Shares awarded in 2018 under the
Company's Performance Share Plan, Ms Conrad received a cash amount
of £115,778.84 (less applicable tax withholding) which is
equal to the market value of the number of Ordinary Shares which
would otherwise have been transferred to her.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
9,181
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-15
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP
& General Counsel
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2018 under the Company's 2017 Performance Share
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$35.6978
|
2,458
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr N Hirons
|
|||
b)
|
Position/status
|
SVP,
Global Ethics and Compliance
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
23,551
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms S Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications & CEO Office
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
4,316
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Jackson
|
|||
b)
|
Position/status
|
PCA of
Ms S Jackson (SVP, Global Communications & CEO
Office)
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
2,038
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr B McNamara
|
|||
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2018 under the Company's 2017 Performance Share
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$35.6978
|
43,024
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr L Miels
|
|||
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
29,048
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Redfern
|
|||
b)
|
Position/status
|
Chief
Strategy Officer
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
43,533
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Simard
|
|||
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
4,316
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms K Terrell
|
|||
b)
|
Position/status
|
Chief
Digital & Technology Officer
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2018 under the Company's 2017 Performance Share
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$35.6978
|
27,459
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr P Thomson
|
|||
b)
|
Position/status
|
President,
Global Affairs
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
31,041
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Waterhouse
|
|||
b)
|
Position/status
|
CEO of
ViiV Healthcare
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
5,917
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms V Whyte
|
|||
b)
|
Position/status
|
Company
Secretary
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2018 under the Company's 2017 Performance
Share Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£12.6107
|
4,316
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2021-02-12
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
17, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|